Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Long-Term Debt Repayments (2019 - 2021)

Arcadia Biosciences (RKDA) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $114000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Long-Term Debt Repayments rose 1325.0% year-over-year to $114000.0, compared with a TTM value of $2.1 million through Dec 2021, up 6211.76%, and an annual FY2021 reading of $2.1 million, up 6211.76% over the prior year.
  • Long-Term Debt Repayments was $114000.0 for Q4 2021 at Arcadia Biosciences, up from $13000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $2.0 million in Q1 2021 and bottomed at $6000.0 in Q4 2019.
  • Average Long-Term Debt Repayments over 3 years is $242888.9, with a median of $10000.0 recorded in 2021.
  • Peak annual rise in Long-Term Debt Repayments hit 28600.0% in 2021, while the deepest fall reached 18.18% in 2021.
  • Year by year, Long-Term Debt Repayments stood at $6000.0 in 2019, then soared by 33.33% to $8000.0 in 2020, then surged by 1325.0% to $114000.0 in 2021.
  • Business Quant data shows Long-Term Debt Repayments for RKDA at $114000.0 in Q4 2021, $13000.0 in Q3 2021, and $10000.0 in Q2 2021.